# GSK1120212+GSK2141795 for Cervical Cancer

> **NCT01958112** · PHASE2 · TERMINATED · sponsor: **Dana-Farber Cancer Institute** · enrollment: 14 (actual)

## Conditions studied

- Cervical Cancer

## Interventions

- **DRUG:** GSK1120212 (trametinib)
- **DRUG:** GSK2141795

## Key facts

- **NCT ID:** NCT01958112
- **Lead sponsor:** Dana-Farber Cancer Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2013-10
- **Primary completion:** 2017-11
- **Final completion:** 2017-11
- **Target enrollment:** 14 (ACTUAL)
- **Why stopped:** Drug supply
- **Last updated:** 2019-05-31

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01958112

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01958112, "GSK1120212+GSK2141795 for Cervical Cancer". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT01958112. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*